NZ191589A - 5-((r)-1-hydroxy-2-((r)-(1-methyl-3-phenylpropyl)-amino)-ethyl)-salicylamide and derivatives; intermediates; pharmaceutical compositions - Google Patents

5-((r)-1-hydroxy-2-((r)-(1-methyl-3-phenylpropyl)-amino)-ethyl)-salicylamide and derivatives; intermediates; pharmaceutical compositions

Info

Publication number
NZ191589A
NZ191589A NZ191589A NZ19158979A NZ191589A NZ 191589 A NZ191589 A NZ 191589A NZ 191589 A NZ191589 A NZ 191589A NZ 19158979 A NZ19158979 A NZ 19158979A NZ 191589 A NZ191589 A NZ 191589A
Authority
NZ
New Zealand
Prior art keywords
methyl
protected
phenylpropyl
salicylamide
optical isomer
Prior art date
Application number
NZ191589A
Other languages
English (en)
Inventor
E H Gold
W Chang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NZ191589A publication Critical patent/NZ191589A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NZ191589A 1978-09-20 1979-09-17 5-((r)-1-hydroxy-2-((r)-(1-methyl-3-phenylpropyl)-amino)-ethyl)-salicylamide and derivatives; intermediates; pharmaceutical compositions NZ191589A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94451678A 1978-09-20 1978-09-20

Publications (1)

Publication Number Publication Date
NZ191589A true NZ191589A (en) 1984-03-30

Family

ID=25481553

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ191589A NZ191589A (en) 1978-09-20 1979-09-17 5-((r)-1-hydroxy-2-((r)-(1-methyl-3-phenylpropyl)-amino)-ethyl)-salicylamide and derivatives; intermediates; pharmaceutical compositions

Country Status (27)

Country Link
EP (1) EP0009702B1 (cg-RX-API-DMAC7.html)
JP (3) JPS5555147A (cg-RX-API-DMAC7.html)
KR (2) KR830000904A (cg-RX-API-DMAC7.html)
AT (1) ATE351T1 (cg-RX-API-DMAC7.html)
AU (1) AU528626B2 (cg-RX-API-DMAC7.html)
CA (1) CA1151211A (cg-RX-API-DMAC7.html)
CY (1) CY1175A (cg-RX-API-DMAC7.html)
DD (1) DD150457A5 (cg-RX-API-DMAC7.html)
DE (1) DE2961263D1 (cg-RX-API-DMAC7.html)
DK (1) DK387579A (cg-RX-API-DMAC7.html)
FI (1) FI792884A7 (cg-RX-API-DMAC7.html)
GR (1) GR73179B (cg-RX-API-DMAC7.html)
HK (1) HK13383A (cg-RX-API-DMAC7.html)
HU (1) HU185523B (cg-RX-API-DMAC7.html)
IE (1) IE49301B1 (cg-RX-API-DMAC7.html)
IL (1) IL58258A (cg-RX-API-DMAC7.html)
KE (1) KE3283A (cg-RX-API-DMAC7.html)
MY (1) MY8500042A (cg-RX-API-DMAC7.html)
NO (1) NO149660C (cg-RX-API-DMAC7.html)
NZ (1) NZ191589A (cg-RX-API-DMAC7.html)
OA (1) OA06339A (cg-RX-API-DMAC7.html)
PH (1) PH16794A (cg-RX-API-DMAC7.html)
PL (1) PL129114B1 (cg-RX-API-DMAC7.html)
PT (1) PT70191A (cg-RX-API-DMAC7.html)
SG (1) SG283G (cg-RX-API-DMAC7.html)
YU (1) YU227379A (cg-RX-API-DMAC7.html)
ZA (1) ZA794872B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658060A (en) * 1982-04-26 1987-04-14 Schering Corporation Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide
IT1194406B (it) * 1983-09-27 1988-09-22 Scharper S P A Procedimento per la preparazione di 2-idrossi-5-01-idrossi-2-((4-fenil-2-butil)ammino) etil benzammide
HU190867B (en) * 1984-01-20 1986-11-28 Egyt Gyogyszervegyeszeti Gyar,Hu Process for preparing 2-hydroxy-5-/1-hydroxy-2-/1-methyl-3-phenyl-propyl/-amino/ethyl/-benzamide and pharmaceutically acceptable salts thereof
US4788183A (en) * 1987-11-30 1988-11-29 Schering Corporation Method for treatment of dyslipidemia in humans
US4879233A (en) * 1989-02-10 1989-11-07 Schering Corporation Novel Aspergillus niveus microorganism used for the chiral reduction of carbonyl groups
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
ATE312347T1 (de) * 1991-08-23 2005-12-15 Nps Pharma Inc Screening-verfahren für kalzium-rezeptor aktive verbindungen
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP0787122B9 (en) 1994-10-21 2007-10-17 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
EP0907631B1 (en) 1996-05-01 2003-06-18 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
IT1313583B1 (it) 1999-07-30 2002-09-09 Chiesi Farma Spa Derivati 2-amminotetralinici per la terapia del glaucoma.
DK1961735T3 (da) * 2007-02-22 2010-03-29 Indena Spa Fremgangsmåde til fremstilling af (2R,3S)-3-phenylisoserinmethylesteracetatsalt
WO2012021629A2 (en) * 2010-08-11 2012-02-16 Philadelphia Health & Education Corporation Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2016077461A2 (en) * 2014-11-11 2016-05-19 Western University Of Health Sciences Isoform-specific calpain inhibitors, methods of identification, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1266058A (cg-RX-API-DMAC7.html) * 1969-07-08 1972-03-08
US4012444A (en) * 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
JPS51128937A (en) * 1975-04-17 1976-11-10 Scherico Ltd Diastereomer of phenylaminoethanol derivatives

Also Published As

Publication number Publication date
NO792993L (no) 1980-03-21
DK387579A (da) 1980-03-21
PH16794A (en) 1984-02-28
JPH0210128B2 (cg-RX-API-DMAC7.html) 1990-03-06
NO149660B (no) 1984-02-20
KR830000904A (ko) 1983-04-28
DE2961263D1 (en) 1982-01-14
JPS5555147A (en) 1980-04-22
ATE351T1 (de) 1981-11-15
YU227379A (en) 1983-06-30
IL58258A0 (en) 1979-12-30
FI792884A7 (fi) 1981-01-01
HK13383A (en) 1983-04-29
JPS59108749A (ja) 1984-06-23
OA06339A (fr) 1981-06-30
SG283G (en) 1983-09-16
IE49301B1 (en) 1985-09-18
CA1151211A (en) 1983-08-02
PL218408A1 (cg-RX-API-DMAC7.html) 1980-09-08
EP0009702A1 (en) 1980-04-16
PT70191A (en) 1979-10-01
HU185523B (en) 1985-02-28
AU528626B2 (en) 1983-05-05
DD150457A5 (de) 1981-09-02
MY8500042A (en) 1985-12-31
KR890001998B1 (ko) 1989-06-07
CY1175A (en) 1983-06-10
KE3283A (en) 1983-05-13
JPH02167253A (ja) 1990-06-27
NO149660C (no) 1984-05-30
KR840005307A (ko) 1984-11-05
GR73179B (cg-RX-API-DMAC7.html) 1984-02-14
ZA794872B (en) 1980-11-26
IL58258A (en) 1984-01-31
AU5088179A (en) 1980-03-27
EP0009702B1 (en) 1981-11-04
PL129114B1 (en) 1984-03-31
IE791770L (en) 1980-03-20

Similar Documents

Publication Publication Date Title
NZ191589A (en) 5-((r)-1-hydroxy-2-((r)-(1-methyl-3-phenylpropyl)-amino)-ethyl)-salicylamide and derivatives; intermediates; pharmaceutical compositions
EP0512901B1 (fr) Composés polycycliques aminés et leurs énantiomères, procédé pour leur préparation et compositions pharmaceutiques en contenant
JP3100165B2 (ja) インドール誘導体
KR100523366B1 (ko) 티에닐아졸일알콕시에탄아민, 이의 제조방법 및 이의 용도
WO1993018002A1 (fr) Sels quaternaires de piperidines 4-substitues, leur preparation et compositions pharmaceutiques les contenant
JPH11502810A (ja) ニューロキニンアンタゴニストとしての３−ベンジルアミノ−２−フェニルピペリジン
HU221634B1 (hu) Nitrogéntartalmú heterociklusos vegyületek fluor-alkoxi-benzilamino-származékai, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
FR2696178A1 (fr) Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
IE41528B1 (en) Benzomorphanes and derivatives and pharmaceutical compositions containing the same
JPS636058B2 (cg-RX-API-DMAC7.html)
EP0168505A1 (en) Substituted 2-aminotetralins and processes for synthesis
NZ231354A (en) S-norfluoxetine, ie. 3-(4-tri fluoromethylphenoxy)-3- phenylpropylamine, salts, solvates, pharmaceutical compositions and preparatory processes thereof
JPH0372467A (ja) ピペラジン誘導体
CA1192224A (en) 2-[2'-HYDROXY-3'-(1,1-DIMETHYLPROPYLAMINO)- PROPOXY]-.beta.-PHENYLPROPIOPHENONE, ITS ACID ADDITION SALTS, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS
JPH0670026B2 (ja) １，４−二置換ピペラジン誘導体、これを含む薬剤組成物およびその製造方法
US4198424A (en) Substituted 1-phenyl-2-pyrrolidin-2-yl-ethanols, their synthesis, their use and their compositions
JP3172543B2 (ja) ２０，２１−ジノルエブルナメニンの新規の誘導体、それらの製造方法及び得られる新規の中間体、それらの薬剤としての使用並びにそれらを含有する組成物
US4619919A (en) Treatment of hypertension
JPH034073B2 (cg-RX-API-DMAC7.html)
US4950783A (en) Treatment of hypertension
EP0948964B1 (en) Novel n-substituted pyrrolidine derivatives and process for preparing the same
CA1064965A (en) Optically active 2,3-cis-1,2,3,4-tetrahydro-5-(2-hydroxy-3-(tert-butylamino)-propoxy)-2,3-naphthalenediols
MC1172A1 (fr) Nouveaux derives de phenyle
JP2005523936A (ja) タムスロシン誘導体
HK1060129B (en) Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same